top of page
.png){kind=small}
A growing collection of the papers, reviews, and scientific literature shaping my understanding of cancer science and engineering. As I prepare for doctoral training, this is where I keep track of what I’m reading, what inspires me, and the questions I hope to explore further in my own research.
HALLMARKS OF CANCER: NEW DIMENSIONS
DOUGLAS HANAHAN, 2021
ADENO-ASSOCIATED VIRUS AS A DELIVERY VECTOR FOR GENE THERAPY OF HUMAN DISEASES
JIANG-HUI WANG, 2024
ENGINEERING ADENO-ASSOCIATED VIRUS VECTORS FOR GENE THERAPY
CHENGWEN LI, 2020
MANUFACTURING CHALLENGES AND RATIONAL FORMULATION DEVELOPMENT FOR AAV VIRAL VECTORS
ARVIND SRIVASTAVA, 2021
PLECTIN-1 TARGETED AAV VECTOR FOR THE MOLECULAR IMAGING OF PANCREATIC CANCER
PRASAD R. KONKALMATT, 2012
COMPREHENSIVE AAV CAPSID FITNESS LANDSCAPE REVEALS A VIRAL GENE AND ENABLES MACHINE-GUIDED DESIGN
PIERCE J. OGDEN, 2019
UNDERSTANDING THE TUMOR IMMUNE MICROENVIRONMENT (TIME) FOR EFFECTIVE THERAPY
MIKHAIL BINNEWIES, 2018
ADENO-ASSOCIATED VIRUS (AAV) VECTORS IN CANCER THERAPY
JORGE L. SANTIAGO, 2016
OVERCOMING THE HOST IMMUNE RESPONSE TO ADENO-ASSOCIATED VIRUS GENE DELIVERY VECTORS: THE RACE BETWEEN CLEARANCE, TOLERANCE, NEUTRALIZATION, AND ESCAPE
FEDERICO MINGOZZI, 2017
FANTASTIC AAV GENE THERAPY VECTORS AND HOW TO FIND THEM: RANDOM DIVERSIFICATION, RATIONAL DESIGN AND MACHINE LEARNING
JONAS BECKER, 2022
OFF-TARGET-FREE GENE DELIVERY BY AFFINITY-PURIFIED RECEPTOR-TARGETED VIRAL VECTORS
ROBERT C. MUNCH, 2015
INTRACRANIAL AAV-IFN-β GENE THERAPY ELIMINATES INVASIVE XENOGRAPH GLIOBLASTOMA AND IMPROVES SURVIVAL IN ORTHOTOPIC SYNGENEIC MURINE MODEL
DWIJIT GUHASARKAR, 2017
ADENO-ASSOCIATED VIRUS (AAV) AS A VECTOR FOR GENE THERAPY
MICHAEL F. NASO, 2017
TOWARDS CLINICAL IMPLEMENTATION OF ADENO-ASSOCIATED VIRUS (AAV) VECTORS FOR CANCER GENE THERAPY: CURRENT STATUS AND FUTURE PERSPECTIVES
ULRICH T. HACKER, 2020
STRATEGIES TO IMPROVE SAFETY PROFILE OF AAV VECTORS
TUISKI SUORANTA, 2022
COMPREHENSIVE AAV CAPSID FITNESS LANDSCAPE REVEALS A VIRAL GENE AND ENABLES MACHINE-GUIDED DESIGN
PIERCE J. OGDEN, 2019
TUMOR-SPECIFIC DELIVERY OF IMMUNE CHECKPOINT INHIBITORS BY ENGINEERED AAV VECTORS
JOHANNA REUL, 2019
bottom of page